IN THE NEWS
Meanwhile, almost a dozen organized labor groups from around the state sent a letter Monday to House and Senate leadership urging them to protect union health plans as Beacon Hill considers cracking down on pharmacy benefit managers as a way to control prescription drug costs.
While pharmaceutical manufacturers should be recognized for discovering life-saving medicines, they are not a reliable source for legislators to make policy changes. Drug companies use many strategies to keep prices and profits high while blaming others in the process. These strategies directly affect patients by protecting drug companies’ profits.
Big Pharma has a new scheme that will make them even more money.
Undermining patients' bargaining power and pointing the finger at anyone standing in their way.
They’ll blame the system. They’ll blame PBMs. They’ll even blame the President of the United States.
If we want to solve the Rx cost crisis - we need to start holding Big Pharma accountable.
Drugmakers kicked off 2024 by raising the list prices for Ozempic, Mounjaro and dozens of other widely used medicines.
Companies including Novo Nordisk, the maker of Ozempic, and Eli Lilly, which sells Mounjaro, raised list prices on 775 brand-name drugs during the first half of January, according to an analysis for The Wall Street Journal by 46brooklyn Research, a nonprofit drug-pricing analytics group.
NEW EMPLOYER SURVEY ON PBM VALUE
The Coalition for Affordable Prescription Drugs (CAPD) released a groundbreaking new poll showing that employers value their PBM. By high margins, employers say they place enormous value on having the option to choose the type of coverage that meets the unique needs of their employees.
READ MORE
Oklahoma can't regulate PBMs' pharmacy networks: federal appeals court
The court’s decision supports the interests of employers, as well as unions and Part D plans, who seek to follow a common set of legal requirements for the benefits they provide to millions of Americans... READ MORE
Prescription prices should be addressed at BIO International Convention
Yet despite the clear demand to address prescription affordability, it seems there are a hundred other topics to discuss as a pharmaceutical and biotech sector at this year’s meeting of the minds. READ MORE
